Dietrich W, Braun S, Spannagl M, Richter J A
Department of Anesthesiology, German Heart Center, Munich, Germany.
Anesth Analg. 2001 Jan;92(1):66-71. doi: 10.1097/00000539-200101000-00013.
We evaluated the interaction of preoperative antithrombin (AT) activity and intraoperative response to heparin in cardiac surgery. Heparin anticoagulation is essential during cardiopulmonary bypass (CPB). Heparin itself has no anticoagulant properties, however it causes a conformational change of the physiologic plasma inhibitor AT that converts this slow-acting serine protease inhibitor into a fast acting one. Thus, adequate AT activity is a prerequisite for sufficient heparin anticoagulation. AT activity is reduced by long-term heparin therapy. This prospective, observational study investigated 1516 consecutive cardiac-surgical patients (1304 patients >1 yr (Group A) and 212 patients < or = 1 yr (Group I)). AT activity was measured the day before surgery by a chromogenic substrate assay. The celite-activated activated clotting time (ACT) was used to guide intraoperative heparin administration. Heparin sensitivity was calculated and the postoperative blood loss and perioperative blood requirement was recorded. Infant patients had significantly less preoperative AT activity compared with older patients: 84 (33)% vs 97 (17)%, median (interquartile range) (P < 0. 05). The subgroup of patients aged <1 mo (n = 64) demonstrated a preoperative AT activity of 56 (27)% as compared with 90 (23)% in infant patients between one month and one year (n = 148). In adult patients, preoperative AT activity depended predominantly on preoperative heparin treatment: 62% of the patients with an AT activity <80% were pretreated with heparin. Five minutes after heparin but before CPB the ACT was 587 (334) s in Group A patients with AT activity > or = 80%, and 516 (232) in patients with AT activity < or = 80% (P < 0.05). The target ACT of 480 s was achieved in 70% of patients with normal AT activity in Group A compared with only 54% of patients with AT activity <80% (P < 0.05). In Group A patients with decreased AT activity, 18% demonstrated an inadequate ACT response-defined as ACT <400 s-to the first bolus injection of heparin. In Group I, preoperative AT activity did not influence the ACT response (ACT 5 min after heparin: 846 [447] s in patients with AT activity > or = 80% vs 1000 [364] s in patients with decreased AT activity). The heparin sensitivity was 2.4 (1.1) s/unit heparin/kg compared with 1.5 (0.8) s/unit heparin/KG in group A (P < 0.05). These results suggest that preoperative diminished AT activity causes reduced response to heparin in adult but not in infant patients. Infant patients demonstrate a higher heparin sensitivity despite lower preoperative AT activity. Measurement of preoperative AT activity identifies adult patients at risk of reduced sensitivity to heparin.
In patients less than one year of age, low antithrombin (AT) activity is caused by the immature coagulation system. Despite low AT activity, these young patients demonstrate a normal or increased response to heparin anticoagulation before cardiopulmonary bypass (CPB). In contrast, in patients older than one year of age and adult patients decreased preoperative AT activity is mainly caused by preoperative heparin therapy and causes insufficient response to heparin anticoagulation with a standard heparin dosage. Measurement of preoperative AT activity identifies patients at risk of inadequate anticoagulation during CPB.
我们评估了心脏手术中术前抗凝血酶(AT)活性与术中对肝素反应之间的相互作用。在体外循环(CPB)期间,肝素抗凝至关重要。肝素本身没有抗凝特性,然而它会引起生理性血浆抑制剂AT的构象变化,将这种作用缓慢的丝氨酸蛋白酶抑制剂转变为作用快速的抑制剂。因此,足够的AT活性是充分肝素抗凝的先决条件。长期肝素治疗会降低AT活性。这项前瞻性观察性研究调查了1516例连续的心脏手术患者(1304例年龄>1岁的患者(A组)和212例年龄≤1岁的患者(I组))。术前一天通过发色底物测定法测量AT活性。用硅藻土激活的活化凝血时间(ACT)来指导术中肝素的给药。计算肝素敏感性,并记录术后失血量和围手术期的血液需求量。与年长患者相比,婴儿患者术前的AT活性明显更低:中位数(四分位间距)为84(33)% 对97(17)%(P<0.05)。年龄<1个月的患者亚组(n = 64)术前AT活性为56(27)%,而1个月至1岁婴儿患者(n = 148)为90(23)%。在成年患者中,术前AT活性主要取决于术前肝素治疗:AT活性<80%的患者中有62%接受过肝素预处理。在A组中,AT活性≥80%的患者在给予肝素5分钟后但在CPB开始前ACT为587(334)秒,而AT活性≤80%的患者为516(232)秒(P<0.05)。A组中AT活性正常的患者有70%达到了480秒的目标ACT,而AT活性<80%的患者只有54%达到(P<0.05)。在A组中AT活性降低的患者中,18%对首次推注肝素的ACT反应不足(定义为ACT<400秒)。在I组中,术前AT活性不影响ACT反应(给予肝素5分钟后的ACT:AT活性≥80%的患者为846[447]秒,而AT活性降低的患者为1000[364]秒)。I组的肝素敏感性为2.4(1.1)秒/单位肝素/千克,而A组为1.5(0.8)秒/单位肝素/千克(P<0.05)。这些结果表明,术前AT活性降低会导致成年患者而非婴儿患者对肝素的反应降低。尽管术前AT活性较低,但婴儿患者表现出更高的肝素敏感性。术前AT活性的测定可识别出对肝素敏感性降低风险的成年患者。
在年龄小于1岁的患者中,低抗凝血酶(AT)活性是由未成熟的凝血系统引起的。尽管AT活性较低,但这些年轻患者在体外循环(CPB)前对肝素抗凝表现出正常或增强的反应。相比之下,在年龄大于1岁的患者和成年患者中,术前AT活性降低主要是由术前肝素治疗引起的,并导致对标准肝素剂量的肝素抗凝反应不足。术前AT活性的测定可识别出CPB期间抗凝不足风险的患者。